USPTO serial 98830251
SYNERGICE MAKE MORE POSSIBLE
Reviewed by CopyMark Law Group
Status 807Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- DEMARCO,JOE P
- Law office
- TMO LAW OFFICE 133
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with SYNERGICE MAKE MORE POSSIBLE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Zach Gordon
Zach Gordon Taft Stettinius & Hollister1 Indiana Square, Suite 3500Indianapolis, IN 46204United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations for treatment of Musculo skeletal pain; pharmaceutical preparations for treatment of cancer; pharmaceutical preparations for treatment of Psychiatric disorders; pharmaceutical preparations for treatment of human immunodeficiency virus (HIV); pharmaceutical preparations for treatment Gastro Intestinal illnesses and disorders; pharmaceutical preparations for treatment of allergies; pharmaceutical preparations for treatment of viral illnesses; pharmaceutical preparations for treatment of bacterial illnesses; pharmaceutical preparations for diabetes management; pharmaceutical preparations for treatment of gout; pharmaceutical preparations for treatment of fungal infections; pharmaceutical preparations for treatment of attention deficit disorder; pharmaceutical preparations for treatment of immune disorders; pharmaceutical preparations for treatment of neurological disorders and neurological illness; pharmaceutical preparations for treatment of cardiovascular illnesses; pharmaceutical preparations for treatment of urological issues; pharmaceutical preparations for treatment of sleep disorders; pharmaceutical preparations for treatment of sexual disorders; pharmaceutical preparations for bronchodilation; pharmaceutical preparations for treatment of thyroid disorders; pharmaceutical preparations for treatment of hormonal disorders; Tablet preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; gelatin capsule preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; powder preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; syrup preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; cream preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes; oral solution preparations for medical purposes for treating Musculo skeletal pain, cancer, Psychiatric disorders, human immunodeficiency virus (HIV), Gastro Intestinal illnesses and disorders, allergies, viral illnesses, bacterial illnesses, gout, fungal infections, attention deficit disorder, immune disorders, neurological disorders and neurological illness, cardiovascular illnesses, urological issues, sleep disorders, sexual disorders, bronchodilation, thyroid disorders, hormonal disorders, and managing diabetes | ACTIVE | Jun 24, 2026 |
| 035 | Business to business services in the nature of generating business leads, business development, providing business information, and business intermediary services in the nature of acting as single point of contact between clients and vendors, all in the field of generic pharmaceuticals | ACTIVE | Jun 24, 2026 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Strides Pharma Science Limited
- Other trademarks owned by Strides Pharma Science Limited
- Other trademarks in Class 005
- Other trademarks in Class 035
- Similar marks named SYNERGICE MAKE MORE POSSIBLE
- Prosecution event GNRN explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 16, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2026 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 16, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 19, 2026 | IUAF | USE AMENDMENT FILED | — |
| Aug 19, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 29, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 28, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jan 28, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 28, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 30, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 3, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 3, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 28, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 2, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 1, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 1, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 1, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 30, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 31, 2024 | NWAP | NEW APPLICATION ENTERED | — |